A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea

Trial Profile

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Omiganan (Primary)
  • Indications Rosacea
  • Focus Adverse reactions
  • Sponsors Cutanea Life Sciences
  • Most Recent Events

    • 30 May 2017 This trial was completed in Sweden, according to European Clinical Trials Database.
    • 03 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top